γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T 细胞可能是 SCLC 治疗的有价值靶点。
英文原题:Is It Unnecessary to Assess Tumor Stroma-Infiltrating Lymphocytes in Localized Lung Adenocarcinomas?
Is It Unnecessary to Assess Tumor Stroma-Infiltrating Lymphocytes in Localized Lung Adenocarcinomas?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管本研究存在局限性,但结果突出表明,TILs 可能不是局限性腺癌的独立预后因素,与肿瘤分期相比,其作用并不重要。
在过去十年中,人们越来越关注肿瘤细胞微环境,尤其是肿瘤间质浸润淋巴细胞(TILs)。本研究旨在评估不同 TILs 亚群和 PD-L1 阳性肿瘤细胞在局限性肺腺癌中的预后影响。
我们进行了一项回顾性描述性研究,纳入2015年至2020年间在同一医院病理科诊断并在胸外科切除的局限性腺癌。采用免疫组化方法检测Fox-P3、CD4、CD8、CD20和CD3分析TILs。此外,使用PD-L1抗体评估肿瘤细胞表达。通过高倍镜(X400)手动计数定量肿瘤内和间质标记的淋巴细胞。随后计算Fox-P3+/CD8+、Fox-P3+/CD4+、FoxP3+/PD-L1+和CD8+/CD4+比值。评估TILs对总生存期(OS)和无复发生存期(ReFS)的预后价值。
共纳入44例局限性腺癌。单因素分析中,影响OS的预后因素包括性别、腺癌亚型、TIL(肿瘤浸润淋巴细胞)评分、TIL分级、PD-L1表达、PD-L1分级、肿瘤微环境中的肿瘤免疫,以及多种免疫标志物的表达:CD3、CD4、CD8、CD20和FoxP3。分析还考虑了FoxP3比值、FIL评分,以及涉及免疫标志物的不同比值,如CD8/CD4比值、FoxP3/CD8比值、FoxP3/CD4比值和FoxP3/PD-L1比值。影响ReFS的预后因素包括性别、腺癌亚型、TIL评分、TIL分级、PD-L1、PD-L1分级、TIM、CD8表达、CD20表达、FIL评分、Fox-P3/CD8比值、Fox-P3/CD4比值和Fox-P3/PD-L1比值。多因素分析未发现OS或ReFS的独立预测因素。
During the last decade, more attention was paid to the tumor cell microenvironment, especially to tumor stroma-infiltrating lymphocytes (TILs). This study aimed to assess the prognostic impact of different TILs subpopulations and PD-L1 positive tumor cells in localized lung adenocarcinomas.
We conducted a retrospective descriptive study, which included localized adenocarcinomas diagnosed in the department of pathology and resected in the Thoracic Surgery Department of the same hospital between 2015 and 2020. TILs were analyzed using the immunohistochemical method for Fox-P3, CD4, CD8, CD20, and CD3. Besides, the PD-L1 antibody was used to assess tumor cell expression. Intra-tumoral and stromal labeled lymphocytes were quantified by manual counting at high magnification (X400). Fox-P3+/CD8+, Fox-P3+/CD4+, FoxP3+/PD-L1+, and CD8+/CD4+ ratios were subsequently calculated. The prognostic value of TILs was assessed with respect to overall survival (OS) and recurrence free survival (ReFS).
A total of 44 localized adenocarcinomas were included. In the univariate analysis, the prognostic factors influencing OS included gender, adenocarcinoma subtype, Tumor-Infiltrating Lymphocyte (TIL) score, TIL grade, PD-L1 expression, PD-L1 grade, tumor immunity in the microenvironment, and the expressions of various immune markers: CD3, CD4, CD8, CD20, and FoxP3. The analysis also considered the FoxP3 ratio, FIL score, and different ratios involving immune markers, such as CD8/CD4 ratio, FoxP3/CD8 ratio, FoxP3/CD4 ratio, and FoxP3/PD-L1 ratio. The prognostic factors influencing the ReFS consisted of gender, the adenocarcinoma subtype, TIL score, TIL grade, PD-L1, PD-L1 grade, TIM, CD8 expression, CD20 expression, FIL score, Fox-P3/CD8 ratio, Fox-P3/CD4 ratio, and Fox-P3/PD-L1 ratio. Multivariate analysis revealed no independent predictive factors of OS or ReFS.
Despite the limitations of this study, the results highlighted that TILs may not represent an independent prognostic factor in localized adenocarcinomas and don't play a major role in comparison to the tumor stage.
MEMBER ACCOUNT
登录成功会直接打开下一页。